

## Draft Guidance on Oxybutynin

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Oxybutynin

**Dosage Form; Route:** Film, extended release; transdermal

**Recommended Studies:** Three studies

1. Type of study: Bioequivalence (BE) study with pharmacokinetic (PK) endpoints  
Design: Single-dose, two-treatment, two-period crossover in vivo  
Strength: 3.9 mg/24 hr  
Subjects: Non-pregnant, non-lactating females

Additional comments:

- In this document, this dosage form is referred to as a transdermal delivery system (TDS) and includes products that may be described elsewhere or known as *patches* or *extended release films*.
- Unless otherwise justified, the oxybutynin TDS should be applied to the same anatomical site on all subjects, selected from among those recommended for dosing in the approved labeling for the reference listed drug (RLD) product, and worn for 96 hours. Applicants should randomize subjects to receive either the test or RLD product in a given study period. When possible, the TDS administered in the second study period should be applied to the same anatomical site as in the first study period, but on the contralateral side of the body.
- Contact of the TDS with the skin is essential for the in vivo performance of the TDS, and the PK may be altered when a TDS loses its adherence to the skin. Therefore, the adhesion of each TDS should be monitored and recorded throughout the PK study. The PK samples should be collected and analyzed from all subjects at all sampling times regardless of the adhesion scores of the TDS. Provisions should be included in the study protocol to ensure that deliberate actions with the intent to re-apply a detached area of the TDS, to apply pressure to the TDS, or to reinforce TDS adhesion with the skin (e.g., overlays) are avoided throughout the study.
- The applicant should follow FDA's current thinking in the guidance "Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA" for the design and conduct of the PK BE study.

**Analytes to measure (in appropriate biological fluid):** Oxybutynin in plasma (achiral assay)

**Bioequivalence based on (90% CI): Oxybutynin**

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** Comparative dissolution testing should be conducted on 12 dosage units each, of the test and RLD products. Information on a dissolution method for this drug product can be found on the FDA Dissolution Methods web site, accessible at: <http://www.accessdata.fda.gov/scripts/cder/dissolution/>.

---

2. Type of study: Adhesion study  
Design: Single-dose, two-treatment, two period crossover in vivo  
Strength: 3.9 mg/24 hr  
Subjects: Non-pregnant, non-lactating females

Additional comments:

- The applicant may elect to evaluate the PK BE (study 1) and the adhesion (study 2) in a single study with a combined purpose, or in independent studies. In either case, the studies should be adequately powered to evaluate the BE, and independently, the comparative assessment of adhesion.
  - The applicant should follow FDA's current thinking in the guidance "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs" for the design and conduct of the independent adhesion study or the combined study to evaluate both PK BE and adhesion.
- 

3. Type of study: Skin irritation and sensitization study  
Design: Randomized, evaluator-blinded, within-subject repeat in vivo  
Strength: 3.9 mg/24 hr (Dose: one-half of a 3.9 mg/24 hr TDS)  
Subjects: Non-pregnant, non-lactating females

Additional comments:

- All test articles (i.e., one half of the 3.9 mg/24-hr test product<sup>1</sup>, one half of the 3.9 mg/24-hr RLD product, optional vehicle TDS,<sup>2</sup> and optional negative control<sup>3</sup>) should be applied simultaneously to each subject at different positions on an application site recommended for dosing in the approved labeling for the RLD product.

---

<sup>1</sup> The test product evaluated should be the actual TDS to be marketed. If the test product has a design that can be cut to a smaller size, OGD recommends cutting the TDS in half.

<sup>2</sup> The optional vehicle TDS should contain all of the inactive ingredients in the test product and be identical to the test product in every manner except for the absence of the active ingredient.

<sup>3</sup> An example of the optional negative control treatment is an occlusion cover or device with normal saline applied on a polyester pad under the cover or within the device chamber.

- Sequential TDS applications should be made to the same application site every 72 to 96 hours, for a total of 21 consecutive days. The final TDS should be removed on Day 22.
- There is insufficient information to determine whether it is safe to simultaneously apply two whole, active, 3.9 mg/24 hr oxybutynin TDS on the same subject during a 21-day skin irritation and sensitization study. Since the RLD product has a matrix design that can be safely cut in half, one half of the RLD product can be used for these studies. If the test product also has a design that can be safely cut to a smaller size, it should also be cut in half, and one half of the test product may be applied simultaneously with one half of a RLD product (to separate skin sites). It would not be acceptable to manufacture a separate batch of the test product in order to use a smaller TDS in this study. If the test product has a design that cannot be safely cut to a smaller size, and/or if a prospective applicant proposes study design different than what is recommended above, the prospective applicant may submit a pre-Abbreviated New Drug Application meeting request to discuss the proposed approach.
- The applicant should follow FDA’s current thinking in the guidance “Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs” for the design and conduct of the skin irritation and sensitization study.

#### **Additional comments relating to all studies:**

In addition to the recommendations in the general guidances referenced above, and the product specific recommendations related to the individual studies, the following product specific recommendations should be considered.

- Exclusion criteria (the applicant may add additional criteria):
  - Medical history of urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma; or being at risk for these conditions
- Provide a listing of the prescription and over-the-counter drug products that are contraindicated during the study, such as:
  - Anticholinergic drugs other than test and RLD products
- Subjects should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergic agents such as oxybutynin are used in a hot environment
- Subjects should be advised that anticholinergic agents such as oxybutynin may produce drowsiness (somnolence) or blurred vision, and to exercise caution in decisions to engage in potentially dangerous activities until they have determined its effects. Subjects should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin.

- Subjects should be informed of the possible adverse events that may occur with the use of oxybutynin TDS (i.e., application site pruritis, dry mouth, constipation, application site erythema, diarrhea, dysuria, application site vesicles).